<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035801</url>
  </required_header>
  <id_info>
    <org_study_id>IN105-CT1-005-09</org_study_id>
    <nct_id>NCT01035801</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients</brief_title>
  <official_title>An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocon Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocon Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether IN-105 (oral insulin) is able to control
      increase in blood glucose after eating a meal. This study will also tell whether single
      tablet of IN-105 is safe for patients with Type 1 diabetes mellitus who are currently taking
      insulin injections.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">February 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (Insulin and Blood Glucose)</measure>
    <time_frame>0-130 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (Insulin and Blood Glucose)</measure>
    <time_frame>0-70 min, 0-190 min and 0-250 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>IN105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prandial Oral Insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Lispro Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN-105</intervention_name>
    <description>Prandial Oral Insulin</description>
    <arm_group_label>IN105</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro Injection</intervention_name>
    <description>Insulin Lispro Injection</description>
    <arm_group_label>Insulin Lispro Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients between the ages of 18-45 years inclusive

          2. Established diagnosis of T1DM for at least 1-year

          3. Body mass index of 18.5-29.9 kg/m2 inclusive

          4. Stable weight with no more than 5 kg gain or loss within 3 months of screening

          5. HbA1c ≤ 8.0%

          6. On stable insulin or an insulin analogue regimen for at least 3 months

        Exclusion Criteria:

          1. Any hypersensitivity or allergy

          2. Positive urine ketones test at screening visit.

          3. ECG abnormality

          4. total daily insulin &gt;1 IU/kg and/or &gt;0.7 IU/Kg of basal insulin and/or &gt;0.6 IU/Kg of
             prandial insulin.

          5. Patient with a clinically significant abnormality

          6. Evidence of severe secondary complications of diabetes

          7. History of drug or alcohol dependence or abuse

          8. Patients currently on systemic or inhaled glucocorticoids or other drugs, which may
             affect glycemic control.

          9. Patients treated with blood-glucose lowering drugs other than insulin or insulin
             analogues in the last 4 weeks prior to screening or during the study

         10. History of two or more severe episodes of hypoglycemia (defined by ADA criteria)
             within 6 months prior to screening and/or patients with history of low blood glucose
             level episodes suggestive of hypoglycemia unawareness (loss of warning symptoms of
             hypoglycemia). Investigator to assess this criterion based on the subject filled
             questionnaire.

         11. Any hospitalization or emergency room visit due to poor diabetes control within 6
             months prior to screening.

         12. Impaired hepatic function (ALT or AST value greater than 2 X Upper limit of reference
             range and/or serum bilirubin ≥1.5 X Upper limit of reference range at the screening
             visit).

         13. Impaired renal function (serum creatinine ≥1.5 X Upper limit of reference range at
             screening).

         14. Hemoglobinopathies, haemolytic anaemia, anaemia of chronic disease, or any factor
             affecting the measurement of HbA1c.

         15. Any electively planned surgery requiring hospitalization during the study period.

         16. Pregnancy, lactation, or planned pregnancy during the study duration.

         17. The patient has received another investigational drug within 6 weeks prior to
             screening

         18. Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or co-operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. K.M. Prasanna Kumar, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>CEO and Consultant Endocrinologist, Bangalore Diabetes Hospital, #16/M, Miller tank Bed Area, Thimmaiah Road, Vasanthnagar, Bangalore-560052</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Aravind R Sosale, DNB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Diacon Hospital,Diabetes Care and Research Centre, 359-360, 19th Main, Ist Block,Rajajinagar,Bangalore-560010.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sanjay Kalra, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bharti Research Institute of Diabetes &amp; Endocrinology (BRIDE), Bharti Hospital, Wazir Chand Colony, Kunjpura, karnal, Hariyana- 132001</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Bipin Kumar Sethi, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Care Hospital, Road 1, Banjara Hills, Hyderabad - 500034</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Neeta Deshpande, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Belgaum Diabetic Centre, Ground floor,Beside mahila Vastu Bhander, Maruti Gali, Belgaum- 590001</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Manish Verma, MD</last_name>
    <phone>91 80 28082808</phone>
    <phone_ext>2342</phone_ext>
    <email>manish.verma@biocon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Sharmitha Krishnamurthy, BDS</last_name>
    <phone>91 80 28082808</phone>
    <phone_ext>2304</phone_ext>
    <email>sharmitha.krishnamurthy@biocon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Bipin Kumar Sethi, MD, DM</last_name>
      <phone>+91 4066258792</phone>
      <email>bipinkumarsethi@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Dr Bipin Kumar Sethi, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bharti Research Institute of Diabetes and Endocrinology</name>
      <address>
        <city>Karnal</city>
        <state>Hariyana</state>
        <zip>132001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sanjay Kalra, MD, DM</last_name>
      <phone>+ 91(184)2268484</phone>
      <email>brideknl@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Sanjay Kalra, MD, DNB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diacon Hospital,(Diabetes Care and Research Centre)</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Aravind R Sosale, DNB</last_name>
      <phone>+91 80 23130553</phone>
      <email>aravindsosale@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr.Aravind R Sosale, DNB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bangalore Diabetes Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. K.M. Prasanna Kumar, MD, DM</last_name>
      <phone>+91 80 22372980</phone>
      <email>dr.kmpk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr.K.M Prasanna Kumar, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belgaum Diabetic Centre</name>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <zip>590001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Neeta Deshpande, MD</last_name>
      <phone>+91 831 2446335</phone>
      <email>neetarohit@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr Neeta Deshpande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <lastchanged_date>August 19, 2010</lastchanged_date>
  <firstreceived_date>December 18, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Dr Manish Verma, Manager</name_title>
    <organization>Biocon Limited</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
